Similar effects are seen due to elevated levels of the oncometabolite D-2-hydroxyglutarate in gliomas with activating variants of the IDH1 and IDH2 genes encoding the isocitrate dehydrogenase enzymes [19, 39]. The gene discussed is IDH2; the disease is central nervous system cancer.